Printer Friendly

ISIS PHARMACEUTICALS ANNOUNCES ISSUANCE OF ANTISENSE PATENT

 ISIS PHARMACEUTICALS ANNOUNCES ISSUANCE OF ANTISENSE PATENT
 CARLSBAD, Calif., Aug. 11 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIP) today announced issuance of U.S. Patent No. 5,138,045 covering novel oligonucleotides. The patent covers a new class of oligonucleotides created by the attachment of various polyamines. Such oligonucleotides can be used as drugs working via antisense or other mechanisms and are expected to show enhanced properties, resulting in improved biological and therapeutic activities. In addition to the broad claim for the chemical composition, examples of therapeutic applications include AIDS (HIV), herpes viruses and papilloma viruses. Also covered is the combination of phosphorothioate oligonucleotides with polyamines.
 "This patent is important in its own right and is one of numerous important patent applications we expect to issue. We have pursued a carefully considered, aggressive patenting strategy that we believe will result in a uniquely valuable patent position for Isis," said Dr. Christopher Mirabelli, senior vice president.
 Isis Pharmaceuticals, Inc., based in northern San Diego County, is engaged in the discovery and development of novel therapeutic products based on antisense oligonucleotides. Isis recently completed its initial Phase I human clinical trials on a new drug, the first antisense drug to be administered to humans, to treat human papillomavirus.
 -0- 8/11/92
 /CONTACT: Christopher K. Mirabelli or B. Lynne Parshall of Isis Pharmaceuticals, 616-931-9200; or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for Isis Pharmaceuticals/
 (ISIP) CO: Isis Pharmaceuticals, Inc. ST: California IN: MTC SU:


SM-SH -- NY016 -- 8843 08/11/92 09:20 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 11, 1992
Words:252
Previous Article:GOLDFIELD ANNOUNCES RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 1992
Next Article:JCPENNEY REPORTS STRONG SECOND QUARTER AS CONSUMERS RESPOND TO VALUE
Topics:


Related Articles
ISIS PHARMACEUTICALS TO RECEIVE HIV ANTISENSE PATENT
ISIS PHARMACEUTICAL STRENGTHENS PROPRIETARY POSITION WITH FOUR PATENT APPROVALS
ISIS PHARMACEUTICALS RECEIVES FOUR PATENT ALLOWANCES FOR NOVEL ANTISENSE CHEMISTRY
ISIS RECEIVES COMPOSITION OF MATTER PATENT ON NOVEL THIRD GENERATION ANTISENSE CHEMISTRY
ISIS RECEIVES PATENT ON ISIS 2302, AN ANTISENSE COMPOUND IN CLINICAL DEVELOPMENT FOR INFLAMMATORY DISEASES
Isis Receives Patent on Antisense Inhibitor of C-raf Kinase, Currently in Phase I Clinical Trials for Cancer
Isis Receives Thirteen Patents Covering Antisense Biology, Chemistry and Combinatorial Chemistry
Issuance of Key Second-Generation Antisense Patent Further Strengthens Isis' Intellectual Property Estate.
Isis Pharmaceuticals Receives $7 Million From Drug Royalty USA, Inc.
Genzyme and Isis Obtain Apolipoprotein B (apoB) Expression Antisense Modulation Patent.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters